ace-011 has been researched along with Anemia--Diamond-Blackfan* in 2 studies
1 review(s) available for ace-011 and Anemia--Diamond-Blackfan
Article | Year |
---|---|
Emerging Therapeutic Approaches for Diamond Blackfan Anemia.
Diamond Blackfan Anemia (DBA) is an inherited erythroid aplasia with onset in childhood. Patients carry heterozygous mutations in one of 19 Ribosomal Protein (RP) genes, that lead to defective ribosome biogenesis and function. Standard treatments include steroids or blood transfusions but the only definitive cure is allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Although advances in HSCT have greatly improved the success rate over the last years, the risk of adverse events and mortality is still significant. Clinical trials employing gene therapy are now in progress for a variety of monogenic diseases and the development of innovative stem cell-based strategies may open new alternatives for DBA treatment as well. In this review, we summarize the most recent progress toward the implementation of new therapeutic approaches for this disorder. We present different DNA- and RNA-based technologies as well as new candidate pharmacological treatments and discuss their relevance and potential applicability for the cure of DBA. Topics: Anemia, Diamond-Blackfan; Animals; Disease Models, Animal; Gene Editing; Gene Expression Regulation; Genetic Therapy; Hematologic Agents; Hematopoietic Stem Cell Transplantation; Humans; Protein Biosynthesis; Recombinant Fusion Proteins; RNA, Messenger; Spliceosomes | 2018 |
1 other study(ies) available for ace-011 and Anemia--Diamond-Blackfan
Article | Year |
---|---|
RAP-011 improves erythropoiesis in zebrafish model of Diamond-Blackfan anemia through antagonizing lefty1.
Diamond-Blackfan Anemia (DBA) is a bone marrow failure disorder characterized by low red blood cell count. Mutations in ribosomal protein genes have been identified in approximately half of all DBA cases. Corticosteriod therapy and bone marrow transplantation are common treatment options for patients; however, significant risks and complications are associated with these treatment options. Therefore, novel therapeutic approaches are needed for treating DBA. Sotatercept (ACE-011, and its murine ortholog RAP-011) acts as an activin receptor type IIA ligand trap, increasing hemoglobin and hematocrit in pharmacologic models, in healthy volunteers, and in patients with β-thalassemia, by expanding late-stage erythroblasts through a mechanism distinct from erythropoietin. Here, we evaluated the effects of RAP-011 in zebrafish models of RPL11 ribosome deficiency. Treatment with RAP-011 dramatically restored hemoglobin levels caused by ribosome stress. In zebrafish embryos, RAP-011 likely stimulates erythropoietic activity by sequestering lefty1 from erythroid cells. These findings identify lefty1 as a signaling component in the development of erythroid cells and rationalize the use of sotatercept in DBA patients. Topics: Activin Receptors, Type II; Anemia, Diamond-Blackfan; Animals; beta-Thalassemia; Disease Models, Animal; Erythropoiesis; Gene Knockdown Techniques; Genes, p53; Humans; Left-Right Determination Factors; Ligands; Recombinant Fusion Proteins; Ribosomal Proteins; Signal Transduction; Zebrafish; Zebrafish Proteins | 2015 |